Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s72. https://doi.org/10.25251/skin.6.supp.72